The Effect of Short-term Lipid Lowering with Atorvastatin on Carotid Artery Intima Media Thickness in Patients with Peripheral Vascular Disease: A Pilot Study

References

• Herbert, P. R., Gaziano, M., Chan, K. S. and Hennekens, C. H. (1997). Cholesterol lowering with statin drugs, risk of stroke and total mortality. JAMA, 278, 313–321.
   PubMed Web of Science ®Google Scholar
• Papadakis, J. A., Mikhailidis, D. P. and Winder, A. F. (1998). Lipids and stroke: neglect of a useful preventive measure? Cardiovasc. Res., 40, 265–271.
   PubMed Web of Science ®Google Scholar
• Chambless, L. E., Heiss, G., Folsom, A. R., Rosamond, W., Szklo, M., Sharrett, A. R. et al. (1997). Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol., 146, 483–494.
   PubMed Web of Science ®Google Scholar
• O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L. and Wolfson, S. K. Jr (1999). Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med., 340, 14–22.
   PubMed Web of Science ®Google Scholar
• Crouse, J. R. III, Byington, R. P., Bond, M. G., Espeland, M. A., Craven, T. E., Sprinkle, J. W. et al. (1995). Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-ID. Am. J. Cardiol., 75, 455–459.
   PubMed Web of Science ®Google Scholar
• Crouse, J. R. III, Byington, R. P., Hoen, H. M. and Furberg, C. D. (1997). Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med., 157, 1305–1310.
   PubMed Web of Science ®Google Scholar
• Alam, R., Yatsu, F. M., Kasturi, R. and Bui, G. (1992). Low and high density lipoprotein metabolism in atherothrombotic brain infarction. Stroke, 23, 1265–1270.
   PubMed Web of Science ®Google Scholar
• Furberg, C. D., Adams, H. P. Jr, Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T. et al. (1994). Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation, 90, 1679–1687.
   PubMed Web of Science ®Google Scholar
• MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J. and Simes, J. (1998). Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation, 97, 1784–1790.
   PubMed Web of Science ®Google Scholar
• Poredos, P., Kek, A. and Verhovec, R. (1997). Morphological and functional changes of the arterial wall in subjects at risk of atherosclerosis and in patients with peripheral arterial occlusive disease. Vasa, 26, 271–276.
   PubMedGoogle Scholar
• Mikhailidis, D. P., Ganotakis, E. S., Spyropoulos, K. A., Jagroop, I. A., Byrne, D. J. and Winder, A. F. (1998). Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int. Angiol., 17, 225–233.
   PubMed Web of Science ®Google Scholar
• Stein, J. H. and McBride, P. E. (1998). Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch. Intent Med., 158, 1301–1306.
   PubMed Web of Science ®Google Scholar
• Wood, D., Durrington, P., Poulter, N., McInnes, G., Rees, A. and Wray, R. on behalf of the Societies (British Cardiac Society, British Hypertension Society, British Hyperlipidaemia Association and British Diabetic Association). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart, 80 (Suppl 2), S1–S29.
   Google Scholar
• Mercuri, M., Bond, M. G., Sirtori, C. R., Veglia, F., Crepaldi, G., Feruglio, F. S. et al. (1996). Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am. J. Med., 101, 627–634.
   PubMed Web of Science ®Google Scholar
• Salonen, R., Nyyssonen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J. S. et al. (1995). Kuopio AtherosclerosisPrevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation, 92, 1758–1764.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383–1389.
   PubMed Web of Science ®Google Scholar
• Igarashi, M., Takeda, Y., Mori, S., Ishibashi, N., Komatsu, E., Takahashi, K. et al. (1997). Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol., 120, 1172–1178.
   PubMed Web of Science ®Google Scholar
• O'Driscoll, G., Green, D. and Taylor, R. R. (1997). Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 1126–1131.
   PubMed Web of Science ®Google Scholar
• Dupuis, J., Tardif, J. C., Cernacek, P. and Theroux, P. (1999). Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 99, 3227–3233.
   PubMed Web of Science ®Google Scholar
• Meade, T. W., Mellows, S., Brozovic, M., Miller, G. J., Chakrabarti, R. R. and North, W. R. et al. (1986). Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 2, 533–537.
   PubMed Web of Science ®Google Scholar
• Kannel, W. B., Wolf, P. A., Castelli, W. P. and D'Agostino, R. B. (1987). Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA, 258, 1183–1186.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Crook, M. A., Nair, D. R., Mikhailidis, D. P. and Winder, A. F. (2000). More on the effect of atorvastatin on plasma fibrinogeninprimaryhypercholesterolaemia. Atherosclerosis, 148, 204.
   PubMed Web of Science ®Google Scholar
• de Lorgeril M., Salen, P., Paillard, F. Lacan, P. and Richard, G. (1999). Lipid-lowering drugs and homocysteine. Lancet, 353, 209–210.
   PubMed Web of Science ®Google Scholar
• Dierkes, J., Westphal, S. and Luley, C. (1999). Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet, 354, 219–220.
   PubMed Web of Science ®Google Scholar
• Fowkes, F. G., Housley, E., Cawood, E. H., Macintyre, C. C., Ruckley, C. V. and Prescott, R. J. (1991). Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol., 20, 384–392.
   PubMed Web of Science ®Google Scholar
• Bainton, D., Sweetnam, P., Baker, I. and Elwood, P. (1994). Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br. Heart J., 72, 128–132.
   PubMedGoogle Scholar
• Norgren, L. (1999). Life expectancy for critical limb ischaemia. In The Durability of Vascular and Endovascular Interventions. W. B. Saunders, London, pp. 163–193.
   Google Scholar